We serve Chemical Name:2,2′-Dithiobis(benzothiazole) CAS:120-78-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,2′-Dithiobis(benzothiazole)
CAS.NO:120-78-5
Synonyms:2,2′-Dithiobis(benzothiazole);2,2′-Disulfanediylbis(1,3-benzothiazol);Mercaptobenztiazyl Ether;Perkacit MBTS;2,2′-Disulfanediylbis(1,3-benzothiazole);Benzothiazol-2-yl disulfide;2,2-Dithiobisbenzothiazole;EINECS 204-424-9;2,2′-Dibenzothiazyl disulfide;2,2′-Dithiobis[benzothiazole];2-(1,3-benzothiazol-2-yldisulfanyl)-1,3-benzothiazole;2,2′-Dibenzothiazolyl Disulfide;1,2-Bis(benzo[d]thiazol-2-yl)disulfane;2,2′-Dithiobisbenzothiazole;Benzothiazole, 2,2′-dithiobis-;MFCD00022874;2,2′-Dithiobis(benzothiazole);MBTS
Molecular Formula:C14H8N2S4
Molecular Weight:332.487
HS Code:2934200090
Physical and Chemical Properties:
Melting point:177-180 °C(lit.)
Boiling point:532.5±33.0 °C at 760 mmHg
Density:1.6±0.1 g/cm3
Index of Refraction:1.849
PSA:132.86000
Exact Mass:331.957031
LogP:7.04
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3077 9/PG 3
Packing Group:
Contact us for information like 2,2′-Dithiobis(benzothiazole) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MBTS physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MBTS Use and application,2,2′-Disulfanediylbis(1,3-benzothiazole) technical grade,usp/ep/jp grade.
Related News: Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300. 2,2′-Dithiobis(benzothiazole) manufacturer We found over half the products we tested contained elevated fluorine levels,” Bruton said.
The cosmetic categories that had the highest percentage of 213 high fluorine products were foundations (63%), eye products (58%), mascaras (47%), and lip products (55%), the study found.
Even more concerning was that cosmetics containing high levels of fluorine more often than not failed to disclose any PFAS chemicals on their labels, Bruton noted.
Further analysis of 29 cosmetics with high fluorine levels revealed that they contained between four and 13 specific PFAS chemicals, researchers found. However, only 1 of the 29 products listed PFAS as an ingredient on the product label.
“Even if a consumer is doing their due diligence and trying to avoid harmful chemicals by reading labels, our work is showing that these harmful chemicals are often not disclosed,” Bruton said.
Despite this, Bruton recommends that consumers who want to limit their exposure to PFAS read the labels anyway, to at least avoid products where the chemicals are accurately listed.
High levels of fluorine were frequently found in products advertised as “long-lasting” and “wear-resistant,” which could provide another clue for discerning consumers.
But in the end, there’s not much consumers can do to solve the problem.
“It’s important that the government step up to regulate ingredients in cosmetics with more stringency,” Bruton said. “It’s also time the cosmetics industry steps up and begins efforts to move away from this class of chemicals. 2,2′-Dithiobis(benzothiazole) supplier Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300. 2,2′-Dithiobis(benzothiazole) vendor ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. 2,2′-Dithiobis(benzothiazole) factory Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.
The cosmetic categories that had the highest percentage of 213 high fluorine products were foundations (63%), eye products (58%), mascaras (47%), and lip products (55%), the study found.
Even more concerning was that cosmetics containing high levels of fluorine more often than not failed to disclose any PFAS chemicals on their labels, Bruton noted.
Further analysis of 29 cosmetics with high fluorine levels revealed that they contained between four and 13 specific PFAS chemicals, researchers found. However, only 1 of the 29 products listed PFAS as an ingredient on the product label.
“Even if a consumer is doing their due diligence and trying to avoid harmful chemicals by reading labels, our work is showing that these harmful chemicals are often not disclosed,” Bruton said.
Despite this, Bruton recommends that consumers who want to limit their exposure to PFAS read the labels anyway, to at least avoid products where the chemicals are accurately listed.
High levels of fluorine were frequently found in products advertised as “long-lasting” and “wear-resistant,” which could provide another clue for discerning consumers.
But in the end, there’s not much consumers can do to solve the problem.
“It’s important that the government step up to regulate ingredients in cosmetics with more stringency,” Bruton said. “It’s also time the cosmetics industry steps up and begins efforts to move away from this class of chemicals. 2,2′-Dithiobis(benzothiazole) supplier Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300. 2,2′-Dithiobis(benzothiazole) vendor ��CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,�� said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. 2,2′-Dithiobis(benzothiazole) factory Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications.
